{"entity":{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","aka":[],"tldr":"Maia Biotechnology is a United States-based biotechnology company running 2 late-stage cancer trials in non-small-cell lung cancer.","summary":"Maia Biotechnology, based in Chicago, the United States, is a biotechnology company. Maia Biotechnology is a clinical-stage biopharmaceutical company that develops telomere-targeting immunotherapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in non-small-cell lung cancer. The largest, NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.maiabiotech.com"},{"label":"ClinicalTrials.gov: trials led by Maia Biotechnology","url":"https://clinicaltrials.gov/search?lead=Maia%20Biotechnology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06908304","nct05208944"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Chicago","country":"US","companyType":"biotech","website":"https://www.maiabiotech.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/maia-biotechnology/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"trial":[{"id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/"},{"id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/"}]}}